CMPS vs. ANIP, DAWN, ADPT, RCUS, CALT, SYRE, SPRY, OCUL, XNCR, and ETNB
Should you be buying COMPASS Pathways stock or one of its competitors? The main competitors of COMPASS Pathways include ANI Pharmaceuticals (ANIP), Day One Biopharmaceuticals (DAWN), Adaptive Biotechnologies (ADPT), Arcus Biosciences (RCUS), Calliditas Therapeutics AB (publ) (CALT), Spyre Therapeutics (SYRE), ARS Pharmaceuticals (SPRY), Ocular Therapeutix (OCUL), Xencor (XNCR), and 89bio (ETNB). These companies are all part of the "pharmaceutical products" industry.
COMPASS Pathways vs.
ANI Pharmaceuticals (NASDAQ:ANIP) and COMPASS Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation, risk and community ranking.
ANI Pharmaceuticals has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500. Comparatively, COMPASS Pathways has a beta of 2.28, meaning that its share price is 128% more volatile than the S&P 500.
76.1% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 46.2% of COMPASS Pathways shares are owned by institutional investors. 12.7% of ANI Pharmaceuticals shares are owned by company insiders. Comparatively, 4.3% of COMPASS Pathways shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
ANI Pharmaceuticals presently has a consensus price target of $77.71, suggesting a potential upside of 34.13%. COMPASS Pathways has a consensus price target of $30.60, suggesting a potential upside of 626.84%. Given COMPASS Pathways' higher probable upside, analysts clearly believe COMPASS Pathways is more favorable than ANI Pharmaceuticals.
ANI Pharmaceuticals received 372 more outperform votes than COMPASS Pathways when rated by MarketBeat users. However, 80.52% of users gave COMPASS Pathways an outperform vote while only 64.39% of users gave ANI Pharmaceuticals an outperform vote.
In the previous week, ANI Pharmaceuticals and ANI Pharmaceuticals both had 10 articles in the media. ANI Pharmaceuticals' average media sentiment score of 0.49 beat COMPASS Pathways' score of 0.16 indicating that ANI Pharmaceuticals is being referred to more favorably in the media.
COMPASS Pathways has a net margin of 0.00% compared to ANI Pharmaceuticals' net margin of -1.28%. ANI Pharmaceuticals' return on equity of 15.87% beat COMPASS Pathways' return on equity.
ANI Pharmaceuticals has higher revenue and earnings than COMPASS Pathways. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than COMPASS Pathways, indicating that it is currently the more affordable of the two stocks.
Summary
ANI Pharmaceuticals beats COMPASS Pathways on 10 of the 15 factors compared between the two stocks.
Get COMPASS Pathways News Delivered to You Automatically
Sign up to receive the latest news and ratings for CMPS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
COMPASS Pathways Competitors List
Related Companies and Tools
This page (NASDAQ:CMPS) was last updated on 2/22/2025 by MarketBeat.com Staff
